Correction: Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer

Br J Cancer. 2025 Aug;133(2):274. doi: 10.1038/s41416-025-03092-4.
No abstract available

Publication types

  • Published Erratum